Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide during emergency PCI in AMI with type 2 diabetes
ChiCTR2400091620Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of semaglutide in myocardial infarction (MI) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Assessment of ventricular remodeling by UCG. Started Nov 2024; status: recruiting.
02
Drugs
03
Conditions
myocardial infarction (MI)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400091620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091620.